
Figure 4: Polarized light Microscopy of the trehalose/GDF-5 formulation, example 6, showing the desirable amorphous state of the trehalose.




Lyophilized formulation: example 6, rhGDF-5 conc.: 0.5 mg/vial, trehalose 50 mg/ 0.5 mg of rhGDF-5, pH 2.9

Figure 5: Polarized light Microscopy of the Mannitol/GDF-5 formulation, example 7, showing the undesirable crystallized state of mannitol.




Lyophilized formulation: example 7, rhGDF-5 conc.: 0.5 mg/vial, Mannitol 50 mg/ 0.5 mg of rhGDF-5, pH 2.9

Figure 4: Polarized light Microscopy of the trehalose/GDF-5 formulation, example 6, showing the desirable amorphous state of the trehalose.



Lyophilized formulation: example 6, rhGDF-5 conc.: 0.5 mg/vial, trehalose 50 mg/ 0.5 mg of rhGDF-5, pH 2.9

Figure 5: Polarized light Microscopy of the Mannitol/GDF-5 formulation, example 7, showing the undesirable crystallized state of mannitol.



Lyophilized formulation: example 7, rhGDF-5 conc.: 0.5 mg/vial, Mannitol 50 mg/ 0.5 mg of rhGDF-5, pH 2.9